These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 35232893)

  • 1. The association between osteoporosis medications and lowered all-cause mortality after hip or vertebral fracture in older and oldest-old adults: a nationwide population-based study.
    Li CC; Hsu JC; Liang FW; Chang YF; Chiu CJ; Wu CH
    Aging (Albany NY); 2022 Mar; 14(5):2239-2251. PubMed ID: 35232893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study.
    McClung MR; O'Donoghue ML; Papapoulos SE; Bone H; Langdahl B; Saag KG; Reid IR; Kiel DP; Cavallari I; Bonaca MP; Wiviott SD; de Villiers T; Ling X; Lippuner K; Nakamura T; Reginster JY; Rodriguez-Portales JA; Roux C; Zanchetta J; Zerbini CAF; Park JG; Im K; Cange A; Grip LT; Heyden N; DaSilva C; Cohn D; Massaad R; Scott BB; Verbruggen N; Gurner D; Miller DL; Blair ML; Polis AB; Stoch SA; Santora A; Lombardi A; Leung AT; Kaufman KD; Sabatine MS;
    Lancet Diabetes Endocrinol; 2019 Dec; 7(12):899-911. PubMed ID: 31676222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Refracture risk and all-cause mortality after vertebral fragility fractures: Anti-osteoporotic medications matter.
    Tai TW; Tsai YL; Shih CA; Li CC; Chang YF; Huang CF; Cheng TT; Hwang JS; Lu TH; Wu CH
    J Formos Med Assoc; 2023; 122 Suppl 1():S65-S73. PubMed ID: 37120337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world effectiveness of anti-osteoporosis medications for the prevention of incident hip and clinical vertebral fractures in patients on long-term glucocorticoid therapy: A nationwide health insurance claims database study in Japan.
    Iki M; Fujimori K; Nakatoh S; Tamaki J; Ishii S; Okimoto N; Kamiya K; Ogawa S
    Bone; 2023 Jan; 166():116605. PubMed ID: 36347433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased fracture risk after discontinuation of anti-osteoporosis medications among hip fracture patients: A population-based cohort study.
    Fu SH; Wang CY; Hung CC; Lee CC; Yang RS; Huang CC; Farn CJ; Lin WH; Chen HM; Hsiao FY; Lin JW; Li CY
    J Intern Med; 2021 Dec; 290(6):1194-1205. PubMed ID: 34237171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Delayed initiation of anti-osteoporosis medications increases subsequent hip and vertebral fractures in patients on long-term glucocorticoid therapy: A nationwide health insurance claims database study in Japan.
    Iki M; Fujimori K; Nakatoh S; Tamaki J; Ishii S; Okimoto N; Kamiya K; Ogawa S
    Bone; 2022 Jul; 160():116396. PubMed ID: 35351673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A survey of outcomes and management of patients post fragility fractures in China.
    Wang O; Hu Y; Gong S; Xue Q; Deng Z; Wang L; Liu H; Tang H; Guo X; Chen J; Jia X; Xu Y; Lan L; Lei C; Dong H; Yuan G; Fu Q; Wei Y; Xia W; Xu L
    Osteoporos Int; 2015 Nov; 26(11):2631-40. PubMed ID: 25966892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of osteoporosis after hip fracture is associated with lower all-cause mortality: A nationwide population study.
    Tai TW; Li CC; Huang CF; Chan WP; Wu CH
    Bone; 2022 Jan; 154():116216. PubMed ID: 34571203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparisons Between Different Anti-osteoporosis Medications on Postfracture Mortality: A Population-Based Study.
    Wu CH; Li CC; Hsu YH; Liang FW; Chang YF; Hwang JS
    J Clin Endocrinol Metab; 2023 Mar; 108(4):827-833. PubMed ID: 36317591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Impact of Various Anti-Osteoporosis Drugs on All-Cause Mortality After Hip Fractures: A Nationwide Population Study.
    Tai TW; Hwang JS; Li CC; Hsu JC; Chang CW; Wu CH
    J Bone Miner Res; 2022 Aug; 37(8):1520-1526. PubMed ID: 35689432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug adherence and treatment duration for denosumab and mortality risk among hip fracture patients.
    Tsai YL; Wu CH; Li CC; Shih CA; Chang YF; Hwang JS; Tai TW
    Osteoporos Int; 2023 Oct; 34(10):1783-1791. PubMed ID: 37466659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-Osteoporosis Medications Associated with Decreased Mortality after Hip Fracture.
    Wang PW; Li YZ; Zhuang HF; Yu HM; Cai SQ; Xu H; Chen ZH; Lin JK; Yao XD
    Orthop Surg; 2019 Oct; 11(5):777-783. PubMed ID: 31429532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fracture types affect clinical outcomes of patients managed within the fracture liaison and osteoporosis medication management services.
    Chang CB; Yang RS; Chang LY; Peng JK; Tsai KS; Huang WJ; Yang TH; Chan DC
    Sci Rep; 2019 Jul; 9(1):10089. PubMed ID: 31300660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of previous fracture and anti-osteoporotic medication prescription in hip fracture patients.
    McCarthy CJ; Kelly MA; Kenny PJ
    Ir J Med Sci; 2022 Feb; 191(1):247-252. PubMed ID: 33687665
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-osteoporosis medication treatment pattern after osteoporotic fracture during 2010-2016 in Fujian, China.
    Wang X; Li C; He Y; Wang T; Zhang H; Ma Z; Ma H; Zhao H
    Arch Osteoporos; 2020 Aug; 15(1):134. PubMed ID: 32820451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A national study on long-term osteoporosis therapy and risk of recurrent fractures in patients with hip fracture.
    Hsu CL; Chen HM; Chen HJ; Chou MY; Wang YC; Hsu YH; Liang CK; Chu CS
    Arch Gerontol Geriatr; 2020; 88():104021. PubMed ID: 32058125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fractures and mortality in relation to different osteoporosis treatments.
    Yun H; Delzell E; Saag KG; Kilgore ML; Morrisey MA; Muntner P; Matthews R; Guo L; Wright N; Smith W; Colón-Emeric C; O'Connor CM; Lyles KW; Curtis JR
    Clin Exp Rheumatol; 2015; 33(3):302-9. PubMed ID: 25068266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hip and other fragility fracture incidence in real-world teriparatide-treated patients in the United States.
    Burge RT; Disch DP; Gelwicks S; Zhang X; Krege JH
    Osteoporos Int; 2017 Mar; 28(3):799-809. PubMed ID: 28028555
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of Osteoporosis Medication Use After Hip Fracture With Prevention of Subsequent Nonvertebral Fractures: An Instrumental Variable Analysis.
    Desai RJ; Mahesri M; Abdia Y; Barberio J; Tong A; Zhang D; Mavros P; Kim SC; Franklin JM
    JAMA Netw Open; 2018 Jul; 1(3):e180826. PubMed ID: 30646034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Visualisation of the unmet treatment need of osteoporotic fracture in Taiwan: A nationwide cohort study.
    Wang CY; Fu SH; Huang CC; Hung CC; Yang RS; Hsiao FY
    Int J Clin Pract; 2018 Oct; 72(10):e13246. PubMed ID: 30144247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.